130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Rank Status Study
21 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
22 Completed Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: HIV-1 gag DNA plus IL-12 DNA adjuvant;   Biological: CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine);   Biological: Sodium chloride injection (0.9%)
23 Completed A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: Placebo version of  rgp120/HIV-1MN;   Biological: Placebo version of rgp120/HIV-1SF2
24 Completed Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers
Condition: HIV Infections
Interventions: Biological: DNA-C;   Biological: NYVAC-C
25 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1
26 Completed The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys
Condition: HIV Infections
Interventions: Biological: gp160 MN/LAI-2;   Biological: Aluminum hydroxide
27 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)
Condition: HIV Infections
Interventions: Biological: TBC-3B Vaccine;   Biological: Smallpox Vaccine
28 Active, not recruiting Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
Condition: HIV Infections
Interventions: Biological: DNA Vaccine;   Biological: DNA Vaccine placebo;   Biological: rAd35;   Biological: rAd35 placebo;   Biological: rAd5;   Biological: rAd5 placebo
29 Completed A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection
Condition: HIV Infections
Interventions: Biological: MVA-B;   Biological: Placebo
30 Completed Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
Condition: HIV Infections
Interventions: Biological: SAAVI DNA-C2 vaccine;   Biological: SAAVI MVA-C vaccine;   Biological: Placebo
31 Completed A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
32 Completed A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
Condition: HIV Infections
Intervention: Biological: HIV-1 C4-V3 Polyvalent Peptide Vaccine
33 Completed A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: APL 400-047;   Drug: Bupivacaine hydrochloride
34 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
Condition: HIV Infections
Interventions: Biological: gp160 Vaccine (Immuno-AG);   Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: HIVAC-1e
35 Completed Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
Condition: HIV Infections
Interventions: Biological: EP HIV-1043;   Biological: EP HIV-1090
36 Active, not recruiting Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rAd35 Env A;   Biological: rAd5 Env A;   Biological: rAd5 Env B
37 Completed A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects
Condition: HIV Infections
Intervention: Biological: HIV-1 Peptide Vaccine, Microparticulate Monovalent
38 Completed Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein
Condition: HIV Infections
Intervention: Biological: Biologically active recombinant Tat protein
39 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV gp160MN (vCP125);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
40 Completed A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
Condition: HIV Infections
Intervention: Other: Observation

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years